Thermo Fisher Scientific is an industry-leading, trusted partner offering innovative products and technologies for vaccine development. With the coronavirus (2019-nCov) outbreak, we are committed to helping researchers interested in rapidly developing mRNA-based vaccines with secure supply chains of critical raw materials for mRNA therapeutics.
Our GeneArt Gene Synthesis materials are produced using cutting edge semi-conductor technology. Using femtomole quantities, our processes help reduce errors associated with high-throughput gene synthesis.
TheraPure-grade reagents for mRNA therapeutics contain highest level of purity and are manufactured using high-definition analytics and tightly controlled purity standards. Our TheraPure-grade portfolio (Table 1) offers a unique integrated solution for mRNA synthesis, optimized to meet fit-for-purpose standards:
Table 1. In vitro transcription TheraPure-grade product portfolio.
|In vitro transcription||Posttranscriptional modification||Template degradation|
|T7 RNA polymerase, TheraPure-grade||Capping enzymes, TheraPure-grade||DNase I, TheraPure-grade|
|RNase inhibitor, TheraPure-grade||2’–O-methyltransferase, TheraPure-grade|
|Inorganic Pyrophosphatase, TheraPure-grade||Poly(A) polymerase, TheraPure-grade|
|ATP, GTP, CTP and UTP, TheraPure-grade|
|Modified nucleotides, TheraPure-grade|
|ARCA (anti-reverse cap analog)|
For Research Use Only. Not for use in diagnostic procedures.